Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART

AIDS

Volumn 21, Issue 7, 2007, Pages 835-843

  Collazos, Julio ^a   Asensi, Víctor ^b   Cartón, José A ^b  

^a HOSPITAL DE GALDAKAO   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Antiretroviral therapy; CD4 cell counts; Gender differences; Outcome; Viral load

Indexed keywords

NELFINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; COMPARATIVE STUDY; CONTROLLED STUDY; DEATH; DISEASE COURSE; FEMALE; GENDER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEX DIFFERENCE; UNSPECIFIED SIDE EFFECT; VIROLOGY; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; NELFINAVIR; PROGNOSIS; PROSPECTIVE STUDIES; SEX CHARACTERISTICS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 34147186323     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3280b0774a     Document Type: Article

References (46)

1. Gilad J, Walfisch A, Borer A, Schlaeffer F. Gender differences and sex-specific manifestations associated with human immunodeficiency virus infection in women. Eur J Obstet Gynecol Reprod Biol 2003; 109:199-205.
2. Napravnik S, Poole C, Thomas JC, Eron JJ Jr. Gender difference in HIV RNA levels: a meta-analysis of published studies. J Acquir Immune Defic Syndr 2002; 31:11-19.
3. Suligoi B. The natural history of human immunodeficiency virus infection among women as compared with men. Sex Transm Dis 1997; 24:77-83.
4. Umeh OC, Currier JS. Sex Differences in HIV: natural history, pharmacokinetics, and drug toxicity. Curr Infect Dis Rep 2005; 7:73-78.
5. Hessol NA, Palacio H. Gender, ethnicity and transmission category variation in HIV disease progression. AIDS 1996; 10 (Suppl A):S69-S74.
6. Lemp GF, Hirozawa AM, Cohen JB, Derish PA, McKinney KC, Hernandez SR. Survival for women and men with AIDS. J Infect Dis 1992; 166:74-79.
7. Schmid M, Twisselmann W, Jacquat BJ, Ledergerber B, Battegay M, Egger M. Sex differences in disease course: analysis of the Swiss HIV cohort study. Schweiz Med Wochenschr 1996; 126:2234-2236.
8. Nicastri E, Angeletti C, Palmisano L, Sarmati L, Chiesi A, Geraci A, et al. Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy. AIDS 2005; 19:577-583.
9. Anastos K, Gange SJ, Lau B, Weiser B, Detels R, Giorgi JV, et al. Association of race and gender with HIV-1 RNA levels and immunologic progression. J Acquir Immune Defic Syndr 2000; 24:218-226.
10. Sterling TR, Lyles CM, Vlahov D, Astemborski J, Margolick JB, Quinn TC. Sex differences in longitudinal human immunode-ficiency virus type 1 RNA levels among seroconverters. J Infect Dis 1999; 180:666-672.
11. Knobel H, Alonso J, Casado JL, Collazos J, González J, Ruiz I, et al. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA study. AIDS 2002; 16:605-613.
12. Loupa CV, Rodriguez B, McComsey G, Gripshover B, Salata RA, Valdez H, et al. Gender differences in human immunodeficiency virus (HIV) RNA and CD4 cell counts among new entrants to HIV care. Clin Microbiol Infect 2006; 12:389-391.
13. Moore AL, Kirk O, Johnson AM, Katlama C, Blaxhult A, Dietrich M, et al. Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. J Acquir Immune Defic Syndr 2003; 32:452-461.
14. Mocroft A, Gill MJ, Davidson W, Phillips AN. Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care? J Acquir Immune Defic Syndr 2000; 24:475-482.
15. Delmas MC, Jadand C, De Vincenzi I, Deveau C, Persoz A, Sobel A, et al. Gender difference in CD4R cell counts persist after HIV-1 infection. SEROCO Study Group. AIDS 1997; 11:1071-1073.
16. Moore AL, Sabin CA, Johnson MA, Phillips AN. Gender and clinical outcomes after starting highly active antiretroviral treatment: a cohort study. J Acquir Immune Defic Syndr 2002; 29:197-202.
17. Moore AL, Mocroft A, Madge S, Devereux H, Wilson D, Phillips AN, et al. Gender differences in virologic response to treatment in an HIV-positive population: a cohort study. J Acquir Immune Defic Syndr 2001; 26:159-163.
18. Finkel DG, John G, Holland B, Slim J, Smith SM. Women have a greater immunological response to effective virological HIV-1 therapy. AIDS 2003; 17:2009-2011.
19. Savés M, Morlat P, Chêne G, Dumon B, Peuchant E. Sex differences in HIV-1 viral load and TNF-alpha plasmatic level? AIDS 1999; 13:1414-1415.
20. Sterling TR, Vlahov D, Astemborski J, Hoover DR, Margolick JB, Quinn TC. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med 2001; 344:720-725.
21. Prins M, Robertson JR, Brettle RP, Aguado IH, Broers B, Boufassa F, et al. Do gender differences in CD4 cell counts matter? AIDS 1999; 13:2361-2364.
22. Clark RA, Squires KE. Gender-specific considerations in the antiretroviral management of HIV-infected women. Expert Rev Anti-infect Ther 2005; 3:213-227.
23. Uppal SS, Verma S, Dhot PS. Normal values of CD4 and CD8 lymphocyte subsets in healthy indian adults and the effects of sex, age, ethnicity, and smoking. Cytometry B Clin Cytom 2003; 52:32-36.
24. Tollerud DJ, Clark JW, Brown LM, Neuland CY, Mann DL, Pankiw-Trost LK, et al. The effects of cigarette smoking on T cell subsets. A population-based survey of healthy caucasians. Am Rev Respir Dis 1989; 139:1446-1451.
25. Farzadegan H, Hoover DR, Astemborski J, Lyles CM, Margolick JB, Markham RB, et al. Sex differences in HIV-1 viral load and progression to AIDS. Lancet 1998; 352:1510-1514.
26. Bush CE, Donovan RM, Markowitz N, Baxa D, Kvale P, Saravolatz LD. Gender is not a factor in serum human immunodeficiency virus type 1 RNA levels in patients with viremia. J Clin Microbiol 1996; 34:970-972.
27. Kuyper LM, Wood E, Montaner JS, Yip B, O'Connell JM, Hogg RS. Gender differences in HIV-1 RNA rebound attributed to incomplete antiretroviral adherence among HIV-infected patients in a population-based cohort. J Acquir Immune Defic Syndr 2004; 37:1470-1476.
28. Junghans C, Low N, Chan P, Witschi A, Vernazza P, Egger M. Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort study. AIDS 1999; 13:2547-2554.
29. Cozzi Lepri A, Pezzotti P, Dorrucci M, Phillips AN, Rezza G. HIV disease progression in 854 women and men infected through injecting drug use and heterosexual sex and followed for up to nine years from seroconversion. Italian Seroconversion Study. Br Med J 1994; 309:1537-1542.
30. Rezza G. Determinants of progression to AIDS in HIV-infected individuals: an update from the Italian Seroconversion Study. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17 (Suppl 1):S13-S16.
31. Hewitt RG, Parsa N, Gugino L. Women's health. The role of gender in HIV progression. AIDS Read 2001; 11:29-33.
32. Garcia de la Hera M, Ferreros I, del Amo J, Garcia de Olalla P, Perez Hoyos S, Muga R, et al. Gender differences in progression to AIDS and death from HIV seroconversion in a cohort of injecting drug users from 1986 to 2001. J Epidemiol Community Health 2004; 58:944-950.
33. Currier JS, Spino C, Grimes J, Wofsy CB, Katzenstein DA, Hughes MD, et al. Differences between women and men in adverse events and CD4R responses to nucleoside analogue therapy for HIV infection. The AIDS Clinical Trials Group 175 Team. J Acquir Immune Defic Syndr 2000; 24:316-324.
34. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
35. Ofotokun I. Sex differences in the pharmacologic effects of antiretroviral drugs: potential roles of drug transporters and phase 1 and 2 metabolizing enzymes. Top HIV Med 2005; 13:79-83.
36. Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol 2004; 44:499-523.
37. Haug NA, Sorensen JL, Lollo ND, Gruber VA, Delucci KL, Hall SM. Gender differences among HIV-positive methadone maintenance patients enrolled in a medication adherence trial. AIDS Care 2005; 17:1022-1029.
38. Godin G, Cote J, Naccache H, Lambert LD, Trottier S. Prediction of adherence to antiretroviral therapy: a one year longitudinal study. AIDS Care 2005; 17:493-504.
39. Berg KM, Demas PA, Howard AA, Schoenbaum EE, Gourevitch MN, Arnsten JH. Gender differences in factors associated with adherence to antiretroviral therapy. J Gen Intern Med 2004; 19:1111-1117.
40. Iliyasu Z, Kabir M, Abubakar IS, Babashani M, Zubair ZA. Compliance to antiretroviral therapy among AIDS patients in Aminu Kano Teaching hospital, Kano, Nigeria. Niger J Med 2005; 14:290-294.
41. Hellinger FJ, Fleishman JA. Location, race, and hospital care for AIDS patients: an analysis of 10 states. Inquiry 2001; 38:319-330.
42. Fleishman JA, Gebo KA, Reilly ED, Conviser R, Mathews CW, Todd KP, et al. Hospital and outpatient health services utilization among HIV-infected adults in care 2000-2002. Med Care 2005; 43 (Suppl 9):III40-III52.
43. Davidson AJ, Bertram SL, Lezotte DC, Marine WM, Rietmeijer CA, Hagglund BB, et al. Comparison of health status, socioeconomic characteristics, and knowledge and use of HIV-related resources between HIV-infected women and men. Med Care 1998; 36:1676-1684.
44. Hellinger FJ. The use of health services by women with HIV infection. Health Serv Res 1993; 28:543-561.
45. Garcia-Sanchez I. Gender differences in HIV/AIDS. Gac Sanit 2004; 18 (Suppl 2):47-54.
46. Schuurman R, Descamps D, Weverling GJ, Kaye S, Tijnagel J, Williams I, et al. Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 1996; 34:3016-3022.